Baidu
map

肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

重磅！多纳非尼可显著延长晚期不可手术肝癌患者生命

2017-09-28 佚名 药时代

多纳非尼可肝癌疗效
关注

九月二十八日上午在厦门举行的中国临床肿瘤协会年会上，四川大学华西医院肿瘤科主任毕锋教授报告了甲苯磺酸多纳非尼治疗晚期不可手术的肝细胞癌II期临床试验的总生存期（OS）随访结果。多纳非尼0.2g和0.3g组的中位OS分别长达12.6和11.8个月。该试验最后一位患者的入组时间为2015年5月7日，截至2017年6月有21位患者的生存时间超过两年。


九月二十八日上午在厦门举行的中国临床肿瘤协会年会上，四川大学华西医院肿瘤科主任毕锋教授报告了甲苯磺酸多纳非尼治疗晚期不可手术的肝细胞癌II期临床试验的总生存期（OS）随访结果。多纳非尼0.2g和0.3g组的中位OS分别长达12.6和11.8个月。该试验最后一位患者的入组时间为2015年5月7日，截至2017年6月有21位患者的生存时间超过两年。

多纳非尼是苏州泽璟生物制药有限公司自主研发的1类化学新药，目前正在南京八一医院秦叔逵教授和华西医院毕锋教授领导下开展III期临床试验。

多纳非尼是多种激酶的抑制剂，既可抑制VEGFR、PDGFR等多种受体酪氨酸激酶的活性，也可直接抑制各种Raf激酶，并抑制下游的丝氨酸-苏氨酸激酶信号传导通路，具有抑制肿瘤细胞增殖和肿瘤血管的形成，发挥双重抑制、多靶点阻断的抗肿瘤作用。

晚期肝癌II期临床试验共入组106例晚期不可手术的肝细胞癌患者，随机后分别接受每天两次的0.2g或0.3g的多纳非尼片口服治疗，其中， 0.2g组（III期临床试验剂量）经独立影像学评估的16周疾病控制率为42.5%， 0.3g组也显示类似疗效。多纳非尼总体安全性良好。

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1992219, encodeId=2323199221959, content=<a href='/topic/show?id=8ccf433e97d' target=_blank style='color:#2F92EE;'>#多纳非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43379, encryptionId=8ccf433e97d, topicName=多纳非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jun 27 00:53:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969008, encodeId=462d19690080e, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue May 15 03:53:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549187, encodeId=9967154918e91, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Sep 30 13:53:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248659, encodeId=852424865961, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/XCopLcwfzefM7BSnRJ4Htepic46XMTM2UluFJvuPpkHgb2omdF4kHkAEC71n3dmY9XNDCib3By2icUwDCsg0dDdZicnvK7tgjicdic/0, createdBy=c9bf1640125, createdName=迪1356, createdTime=Fri Sep 29 05:09:16 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2018-06-27 xue8602

    #多纳非尼#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1992219, encodeId=2323199221959, content=<a href='/topic/show?id=8ccf433e97d' target=_blank style='color:#2F92EE;'>#多纳非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43379, encryptionId=8ccf433e97d, topicName=多纳非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jun 27 00:53:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969008, encodeId=462d19690080e, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue May 15 03:53:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549187, encodeId=9967154918e91, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Sep 30 13:53:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248659, encodeId=852424865961, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/XCopLcwfzefM7BSnRJ4Htepic46XMTM2UluFJvuPpkHgb2omdF4kHkAEC71n3dmY9XNDCib3By2icUwDCsg0dDdZicnvK7tgjicdic/0, createdBy=c9bf1640125, createdName=迪1356, createdTime=Fri Sep 29 05:09:16 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2018-05-15 zhu_jun9837

    #肝癌患者#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1992219, encodeId=2323199221959, content=<a href='/topic/show?id=8ccf433e97d' target=_blank style='color:#2F92EE;'>#多纳非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43379, encryptionId=8ccf433e97d, topicName=多纳非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jun 27 00:53:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969008, encodeId=462d19690080e, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue May 15 03:53:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549187, encodeId=9967154918e91, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Sep 30 13:53:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248659, encodeId=852424865961, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/XCopLcwfzefM7BSnRJ4Htepic46XMTM2UluFJvuPpkHgb2omdF4kHkAEC71n3dmY9XNDCib3By2icUwDCsg0dDdZicnvK7tgjicdic/0, createdBy=c9bf1640125, createdName=迪1356, createdTime=Fri Sep 29 05:09:16 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-30 xxxx1054

    #重磅#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1992219, encodeId=2323199221959, content=<a href='/topic/show?id=8ccf433e97d' target=_blank style='color:#2F92EE;'>#多纳非尼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43379, encryptionId=8ccf433e97d, topicName=多纳非尼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Wed Jun 27 00:53:00 CST 2018, time=2018-06-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1969008, encodeId=462d19690080e, content=<a href='/topic/show?id=4dd7812e8f3' target=_blank style='color:#2F92EE;'>#肝癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=81278, encryptionId=4dd7812e8f3, topicName=肝癌患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3609256, createdName=zhu_jun9837, createdTime=Tue May 15 03:53:00 CST 2018, time=2018-05-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1549187, encodeId=9967154918e91, content=<a href='/topic/show?id=f7879600061' target=_blank style='color:#2F92EE;'>#重磅#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96000, encryptionId=f7879600061, topicName=重磅)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3acc14121561, createdName=xxxx1054, createdTime=Sat Sep 30 13:53:00 CST 2017, time=2017-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=248659, encodeId=852424865961, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/XCopLcwfzefM7BSnRJ4Htepic46XMTM2UluFJvuPpkHgb2omdF4kHkAEC71n3dmY9XNDCib3By2icUwDCsg0dDdZicnvK7tgjicdic/0, createdBy=c9bf1640125, createdName=迪1356, createdTime=Fri Sep 29 05:09:16 CST 2017, time=2017-09-29, status=1, ipAttribution=)]
    2017-09-29 迪1356

    学习了

    0

Baidu
map
Baidu
map
Baidu
map